Schadlich, Peter K.; Zeidler, Henning; Zink, Angela; … - In: PharmacoEconomics 23 (2005) 4, pp. 395-420
Objective: To estimate the 3-year incremental cost effectiveness and cost utility of introducing leflunomide into … compared with excluding leflunomide, with an incremental cost effectiveness of _5004 per ACR20RYG, _9535 per ACR50RYG, _7996 … per ACR70RYG, and an incremental cost utility of _8301 per QALYG, after 3 years. The robustness of the results was shown …